Free Trial
NASDAQ:QNCX

Quince Therapeutics Q1 2025 Earnings Results & Report

Quince Therapeutics logo
$31.73 0.00 (0.00%)
As of 10/13/2026

Quince Therapeutics missed analyst earnings expectations in its Q1 2025 results, released May 13, 2025. The company reported EPS of -$68.00 versus the -$48.00 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

Quince Therapeutics EPS Results

Actual EPS
-$68.00
Consensus EPS
-$48.00
Beat/Miss
Missed by -$20.00
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 6 quarters

Quince Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Quince Therapeutics Q1 2025 Earnings FAQ

Quince Therapeutics (NASDAQ:QNCX) reported earnings of -$68.00 per share for Q1 2025, missing the consensus estimate of -$48.00. The report was announced on Tuesday, May 13, 2025.

Quince Therapeutics Earnings Headlines

The warning signs most investors see too late
Dr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008.tc pixel
See More Quince Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Quince Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quince Therapeutics and other key companies, straight to your email.

About Quince Therapeutics

Quince Therapeutics (NASDAQ:QNCX) is a biotechnology company focused on developing treatments for rare diseases. Its principal program has been EryDex, an investigational therapy designed to deliver dexamethasone sodium phosphate inside a patient’s own red blood cells.

The company developed EryDex for ataxia-telangiectasia, a rare inherited disorder that can cause progressive neurological and immune-system problems. The treatment uses a process intended to load the drug into red blood cells for gradual release. Quince’s program followed its 2023 combination with EryDel, the company that developed the EryDex technology.

EryDex was evaluated in a Phase 3 clinical trial, which did not meet its primary efficacy endpoint. Quince is headquartered in the United States; its work on EryDex grew out of technology developed by EryDel in Europe.

View Quince Therapeutics Profile